TOKYO -- Shares of Japanese drugmaker Eisai fell 13% in Tokyo on Monday following European authority's surprise rejection of its Alzheimer's drug last week.
Pharmaceuticals
Eisai shares fall 13% as EU rejects Alzheimer's drug
High expectations take a hit as regulator fails to follow the U.S., Japan and China
Leqembi has been approved in countries such as the U.S., Japan and China, but the European Medicines Agency has balked at following suit. (Photo by Kento Awashima)
Read Next
Latest on Pharmaceuticals
